Andrea Fuso

Prof. Andrea Fuso

Dept. Experimental Medicine - Sapienza University of Rome
orcid

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2005 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
Andrea FusoAndrea Fuso
Andrea Fuso
LSLaura Seminara
Laura Seminara
RCRosaria A. Cavallaro
Rosaria A. Cavallaro
FDFabrizio D'ANselmi
Fabrizio D'ANselmi
SSSigfrido Scarpa
Sigfrido Scarpa

14 July 2016 in Expert Opinion on Drug Metabolism & Toxicology
Verified
Journal Article
Closed access
Mariano BizzarriMariano Bizzarri
Mariano Bizzarri
Andrea FusoAndrea Fuso
Andrea Fuso
SDSimona Dinicola
Simona Dinicola
ACAlessandra Cucina
Alessandra Cucina
ABArturo Bevilacqua
Arturo Bevilacqua
Introduction: Inositol and its derivatives comprise a huge field of biology. Myo-inositol is not only a prominent component of membrane-incorporated phosphatidylinositol, but participates in its free form, with its isomers or its phosphate derivatives, to a multitude of cellular processes, including ion channel permeability, metabolic homeostasis, mRNA export and translation, cytoskeleton remodeling, stress response. Areas covered: Bioavailability, safety, uptake and metabolism of inositol is discussed emphasizing the complexity of interconnected pathways leading to phosphoinositides, inositol phosphates and more complex molecules, like glycosyl-phosphatidylinositols. Expert opinion: Besides being a structural element, myo-inositol exerts unexpected functions, mostly unknown. However, several reports indicate that inositol plays a key role during phenotypic transitions and developmental phases. Furthermore, dysfunctions in the regulation of inositol metabolism have been implicated in several chronic diseases. Clinical trials using inositol in pharmacological doses provide amazing results in the management of gynecological diseases, respiratory stress syndrome, Alzheimer’s disease, metabolic syndrome, and cancer, for which conventional treatments are disappointing. However, despite the widespread studies carried out to identify inositol-based effects, no comprehensive understanding of inositol-based mechanisms has been achieved. An integrated metabolomics-genomic study to identify the cellular fate of therapeutically administered myo-inositol and its genomic/enzymatic targets is urgently warranted.

1 April 2008 in Molecular and Cellular Neuroscience
Verified
Journal Article
Closed access
Andrea FusoAndrea Fuso
Andrea Fuso
VNVincenzina Nicolia
Vincenzina Nicolia
RCRosaria A. Cavallaro
Rosaria A. Cavallaro
LRLaura Ricceri
Laura Ricceri
FDFabrizio D'ANselmi
Fabrizio D'ANselmi
SSSigfrido Scarpa
Sigfrido Scarpa

2 April 2003 in FEBS Letters
Verified
Journal Article
Closed access
SSSigfrido Scarpa
Sigfrido Scarpa
Andrea FusoAndrea Fuso
Andrea Fuso
FDFabrizio D'ANselmi
Fabrizio D'ANselmi
RCRosaria A Cavallaro
Rosaria A Cavallaro

26 August 2009 in Stem Cells
Verified
Journal Article
Open access
PDF file
LGLaura Grisanti
Laura Grisanti
IFIlaria Falciatori
Ilaria Falciatori
MGMargherita Grasso
Margherita Grasso
LDLisa Dovere
Lisa Dovere
SFStefania Fera
Stefania Fera
EVElena Vicini
Elena Vicini
Spermatogenesis is maintained by a pool of spermatogonial stem cells (SSCs). Analyses of the molecular profile of SSCs have revealed the existence of subsets, indicating that the stem cell population is more heterogeneous than previously believed. However, SSC subsets are poorly characterized. In rodents, the first steps in spermatogenesis have been extensively investigated, both under physiological conditions and during the regenerative phase that follows germ cell damage. In the widely accepted model, the SSCs are type Asingle (As) spermatogonia. Here, we tested the hypothesis that As spermatogonia are phenotypically heterogeneous by analyzing glial cell line-derived neurotrophic factor (GDNF) family receptor α1 (GFRA1) expression in whole-mounted seminiferous tubules, via cytofluorimetric analysis and in vivo colonogenic assays. GFRA1 is a coreceptor for GDNF, a Sertoli cell-derived factor essential for SSC self-renewal and proliferation. Morphometric analysis demonstrated that 10% of As spermatogonia did not express GFRA1 but were colonogenic, as shown by germ cell transplantation assay. In contrast, cells selected for GFRA1 expression were not colonogenic in vivo. In human testes, GFRA1 was also heterogeneously expressed in Adark and in Apale spermatogonia, the earliest spermatogonia. In vivo 5-bromo-2′-deoxyuridine administration showed that both GFRA1+ and GFRA1− As spermatogonia were engaged in the cell cycle, a finding supported by the lack of long-term label-retaining As spermatogonia. GFRA1 expression was asymmetric in 5% of paired cells, suggesting that As subsets may be generated by asymmetric cell division. Our data support the hypothesis of the existence of SSC subsets and reveal a previously unrecognized heterogeneity in the expression profile of As spermatogonia in vivo. Disclosure of potential conflicts of interest is found at the end of this article.

1 July 2012 in Neurobiology of Aging
Verified
Journal Article
Closed access
Andrea FusoAndrea Fuso
Andrea Fuso
VNVincenzina Nicolia
Vincenzina Nicolia
LRLaura Ricceri
Laura Ricceri
RCRosaria A. Cavallaro
Rosaria A. Cavallaro
EIElisa Isopi
Elisa Isopi
SSSigfrido Scarpa
Sigfrido Scarpa